Last viewed:
ONCR
Prices are updated after-hours
ONCR
|
$0.126
-75.95%
140K
|
Health Technology
(0.0% 1d)
(0.0% 1m)
(-58.2% 1y)
(0.0% 2d)
(0.0% 3d)
(0.0% 7d)
(755.53%
volume)
Earnings Calendar: 2022-11-02
Market Cap: $ 3,287,951
http://www.oncorus.com
Sec
Filling
|
Patents
| 56 employees
Oncorus, Inc. engages in the research and development of viral immunotherapies platform. It develops immunotherapy platform to treat cancer such as oncolytic Herpes Simplex Virus Platform and Synthetic Virus Platform. The company was founded by Mitchell H. Finer, Joseph C. Glorioso III, Kenneth P. Greenberg, Cyrus D. Mozayeni, and Paola Grandi on April 1, 2015 and is headquartered in Cambridge, MA.
cancer
immunotherapy
add to watch list
Paper trade
email alert is off
Press-releases
Delisting of Securities of Puhui Wealth Investment Management Co., Ltd.; National Energy Services Reunited Corp.; Bed Bath & Beyond Inc.; IMV Inc.; Celyad Oncology SA; Aptinyx Inc.; Athenex, Inc.; Greencity Acquisition Corporation; QualTek Services Inc.; Bellicum Pharmaceuticals, Inc.; Wejo Group Limited; Cyxtera Technologies, Inc.; HTG Molecular Diagnostics, Inc.; Unico American Corporation; PolarityTE, Inc.; Oncorus, Inc.; and OncoSec Medical Incorporated from The Nasdaq Stock Market
Published: 2023-07-06
(Crawled : 20:00)
- globenewswire.com
ONCSQ
|
$0.0001
43900.0%
820
|
Manufacturing
| -99.89%
| O: -15.79%
H: 12.5%
C: -6.25%
CYXTQ
|
$0.0007
-57.14%
1.8K
|
| -98.71%
| O: -4.89%
H: 17.73%
C: -5.28%
QTEKQ
|
$0.012
125.0%
640K
|
Construction
| -36.36%
| O: -17.88%
H: 11.07%
C: -0.37%
ATNXQ
|
$0.0152
-85.53%
3.6K
|
Manufacturing
| -86.19%
| O: 54.31%
H: 0.0%
C: -29.37%
IMVIQ
|
$0.0001
36400.0%
6K
|
Manufacturing
| -100.0%
| O: -18.75%
H: 192.31%
C: 32.62%
ONCR
|
$0.126
-75.95%
140K
|
Health Technology
| 196.13%
| O: -2.05%
H: 29.3%
C: 0.0%
NESR
|
$9.0
500K
|
Industrial Services
| 198.33%
| O: 0.0%
H: 0.0%
C: 0.0%
NDAQ
|
$60.16
0.15%
1.9M
|
Finance
| 22.49%
| O: -0.22%
H: 0.8%
C: 0.18%
BLCM
|
$0.0748
381.28%
6.1K
|
Health Technology
| -79.78%
| O: -14.11%
H: 7.11%
C: 6.2%
management
nasdaq
energy
services
beyond
group
acquisition
medical
molecular
market
Oncorus Announces Workforce Reduction Plan
Published: 2023-06-01
(Crawled : 20:00)
- globenewswire.com
ONCR
|
$0.126
-75.95%
140K
|
Health Technology
| -28.3%
| O: -38.06%
H: 8.99%
C: 1.51%
Oncorus Reports First Quarter 2023 Financial Results and Provides Business Updates
Published: 2023-05-22
(Crawled : 20:00)
- globenewswire.com
ONCR
|
$0.126
-75.95%
140K
|
Health Technology
| -58.66%
| O: -20.51%
H: 7.72%
C: -1.56%
business
financial
results
Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
Published: 2023-03-24
(Crawled : 12:00)
- biospace.com/
ONCR
|
$0.126
-75.95%
140K
|
Health Technology
| -59.39%
| O: 0.06%
H: 12.8%
C: 5.15%
business
year
financial
results
Oncorus Announces Research Collaboration with Daewoong Pharmaceutical for the Development of Lipid Nanoparticle Formulations for mRNA Drug Candidates
Published: 2023-01-04
(Crawled : 21:00)
- biospace.com/
ONCR
|
$0.126
-75.95%
140K
|
Health Technology
| -53.25%
| O: 7.87%
H: 9.73%
C: 0.0%
drug
research
collaboration
mrna
Oncorus Announces Portfolio Reprioritization to Focus on IV-Administered, Self-Amplifying RNA Medicines for Patients with Cancer
Published: 2022-11-30
(Crawled : 13:20)
- biospace.com/
ONCR
|
$0.126
-75.95%
140K
|
Health Technology
| -78.75%
| O: -18.27%
H: 0.0%
C: -3.98%
cancer
Oncorus to Participate in Upcoming Investor Conferences
Published: 2022-11-23
(Crawled : 13:20)
- globenewswire.com
ONCR
|
$0.126
-75.95%
140K
|
Health Technology
| -78.51%
| O: 15.7%
H: 0.0%
C: -14.27%
Oncorus Presents Preclinical Data Supporting ONCR-719, an armed HSV-1 Vector engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry in Glioblastoma, at the 2022 Society for Neuro-Oncology Annual Meeting
Published: 2022-11-18
(Crawled : 13:20)
- globenewswire.com
ONCR
|
$0.126
-75.95%
140K
|
Health Technology
| -78.61%
| O: 5.3%
H: 7.81%
C: 6.72%
oncr-719
preclinical
meeting
growth
glioblastoma
Oncorus Announces Publication in Nature Communications Highlighting the Development of its Intravenously Administered Synthetic vRNA/LNP Platform for the Treatment of Cancer
Published: 2022-10-07
(Crawled : 13:20)
- globenewswire.com
ONCR
|
$0.126
-75.95%
140K
|
Health Technology
| -85.06%
| O: 2.41%
H: 4.38%
C: -10.09%
treatment
communications
cancer
publication
platform
DEM BioPharma Establishes Leadership Team with Appointment of Nenad Grmusa as CEO and Christophe Quéva, Ph.D., as CSO
Published: 2022-09-27
(Crawled : 13:00)
- biospace.com/
ONCR
|
$0.126
-75.95%
140K
|
Health Technology
| -85.24%
| O: 2.16%
H: 8.88%
C: 1.21%
biopharma
ceo
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount